Aflibercept biosimilar - Mabwell (Shanghai) Bioscience
Alternative Names: 9MW-0813Latest Information Update: 12 Apr 2022
Price :
$50 *
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Diabetic macular oedema
Most Recent Events
- 12 Apr 2022 Phase-III clinical trials in Diabetic macular oedema in China (Intraocular) before April 2022 (Mabwell (Shanghai) Bioscience pipeline, April 2022)
- 12 Apr 2022 Mabwell (Shanghai) Bioscience completes enrolment in a phase I trial in Diabetic macular oedema in China (Intravitreous, Injection) (CTR20202549)
- 12 Apr 2022 Mabwell (Shanghai) Bioscience plans a phase III trial for Diabetic macular oedema in China (Intraocular) (CTR20212636)